Happy Spring! As we celebrate CordenPharma’s 20th anniversary in 2026, we recognize that everything we’ve built – our global facility network, scientific depth, and expanding capabilities – has been powered by teamwork, and that teamwork starts with you. Your passion for science, dedication to patients, and relentless drive to innovate are the reasons we continue to grow, invest, and evolve as the CDMO partner you need.
It’s your ambitious pipelines that have inspired us to deliver pioneering technologies across key therapeutic areas for complex modalities such as normal and highly potent small molecule drug substance and drug products, next-generation sterile injectables, as well as innovative peptide, lipid and LNP manufacturing.
Your breakthroughs challenge us to move faster, scale smarter, and integrate drug substance and drug product manufacturing with digitalized, harmonized operations from development to commercialization that reduce risk and bring your therapies to life more reliably than ever. Thank you for the trust you place in our global teams. Your vision fuels our progress, and together we will continue growing to new heights and shaping the future of healthcare for the patients who need us most.
Looking back, 2025 was a defining year for CordenPharma, marked by accelerated growth driven by bold strategic investments across our platforms, outstanding quality performance and innovation.
We delivered strong financial and operational results with €960 million in net sales reflecting 11% CER growth year-over-year, and advanced more than 40 new customer projects. We also reinforced our commitment to quality by completing 10 Health Authority inspections and 80 customer audits. Together, these achievements highlight our focus on growth, partnership, and operational excellence.
In addition, we were honored to receive the European CDMO Leadership Award of the Year, an industry recognition that reflects the strength of our valued customer partnerships. These achievements reinforce our commitment to advancing complex modalities, accelerating development, and simplifying manufacturing for our customers.
Over the past year we advanced our small molecules platform with expanded development and manufacturing capabilities across our global network for both standard and highly potent Small Molecule APIs. New investments strengthened infrastructure and improved flexibility from early development through commercial supply. At the same time, we broadened our Small Molecule Drug Product capabilities with new oral solid dosage lines, enhanced packaging and liquid filling operations, enabling reliable, end‑to‑end supply to customers worldwide.
Our peptide platform is advancing through an unprecedented investment of more than €1 billion over three years to expand small‑, medium‑, and large‑scale peptide manufacturing in the U.S. This transformative program will more than double our SPPS reactor capacity, strengthening our global leadership and supporting our ambition to exceed €1 billion in peptide sales by 2028.
By uniting our expanded peptide development capabilities in Boulder with our our First‑in‑Human peptide drug‑substance–to–injectable‑drug-product clinical trial services in Frankfurt and Caponago, along with advanced oral solid peptide delivery, we offer pharma and biotech partners a fully integrated, end‑to‑end peptide supply chain.
In addition, our innovation efforts were recognized across the industry last year by winning the CPHI 2025 Pharma Award for API Development & Innovation for our TAPS: TAG‑Assisted Peptide Synthesis technology. These strategic expansions and innovations leave us stronger, more capable, and better positioned to shape the future of peptide‑based therapeutics and deliver life‑changing medicines to patients.
In this Q126 edition, we will hear from Andre Durrer, Head of Global Compliance Management Systems in part two of our sustainability video series, on our objectives as laid in our latest sustainability report.
Next, Global Injectables Platform Director Dr. John Cameron will discuss how our injectables platform helps biotechs overcome the hidden risks that slow Sterile Injectable programs, from capacity drift to analytical delays and aseptic challenges. He will share how choosing the right injectable CDMO partner across five critical dimensions can accelerate development, and how our €100M+ investment in new isolator fill and finish lines and planned expansions are designed to eliminate bottlenecks where they matter most.
We will then highlight CordenPharma’s robust approach to Oral Solid Dosage manufacturing across all phases from development to commercialization from our Global Drug Products Platform Head Christian Schmitt.
Finally, you can learn about our uniquely integrated clinical-scale peptide drug substance to injectable drug product offering, ideal for First-in-Human clinical trials. Watch this video with our Peptide and Injectable Platform Heads Dr. Mimoun Ayoub and Dr. John Cameron discussing the advantages this capability brings to developers of peptide-based therapeutics.
As we move into 2026, we look forward to celebrating our 20th Anniversary with you at the upcoming DCAT Week 2026 in New York City or at other CordenPharma events throughout the year. As always, I welcome any suggestions or feedback you might have on how we can better serve you – with the ultimate goal to be your long-term partner, powered by teamwork.
Dr. Michael Quirmbach
President & CEO
CordenPharma Group
Dr. Michael Quirmbach
CEO & President, CordenPharma Group
Get in touch with our team of experts to explore bespoke end-to-end CDMO support of your complete drug lifecycle
at any scale.